表紙
市場調查報告書

抗生素的全球市場 - 抑制劑的種類·藥物類別·各地區:市場分析·佔有率·趨勢·規模·預測

Antibiotics Market, By Inhibitor Types (Protein Synthesis, Cell Wall, DNA, and RNA), By Drug Class and Geography - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025

出版商 AnalystView Market Insights 商品編碼 737901
出版日期 內容資訊 英文 102 Pages
商品交期: 2-3個工作天內
價格
抗生素的全球市場 - 抑制劑的種類·藥物類別·各地區:市場分析·佔有率·趨勢·規模·預測 Antibiotics Market, By Inhibitor Types (Protein Synthesis, Cell Wall, DNA, and RNA), By Drug Class and Geography - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025
出版日期: 2018年09月05日內容資訊: 英文 102 Pages
簡介

本報告提供全球抗生素的市場相關分析,提供市場定義和基本結構,主要的推動及阻礙市場要素,產業的競爭力·向心力,市場佔有率結構,抑制劑類別·各類藥物·各地區的市場趨勢預測 (過去4年·今後8年份),主要企業的簡介等相關調查。

第1章 抗生素市場:概要

第2章 摘要整理

第3章 抗生素市場:主要的市場趨勢

  • 推動市場要素
    • 促進因素的影響度
  • 阻礙市場要素
    • 阻礙因素的影響度
  • 市場機會
  • 市場未來趨勢

第4章 抗生素市場:產業分析

  • 波特的五力分析
  • 市場向心力分析
  • 管理體制分析

第5章 抗生素的市場環境

  • 市場佔有率分析

第6章 抗生素市場:抑制劑類別

  • 概要
  • 蛋白質合成抑制劑
    • 概要
    • 市場規模分析·預測,年度成長率 (以金額為準,總計12年份)
  • 細胞牆抑制劑
  • DNA合成抑制劑
  • RNA合成抑制劑
  • 其他

第7章 抗生素市場:各類藥物

  • 概要
  • Fluoroquinolones
  • 頭孢菌素
  • 青霉素
  • 大環內酯類
  • 碳青霉烯類
  • Aminoglycosides
  • 其他

第8章 抗生素市場:各地區分析

  • 簡介
  • 北美市場 (美國,加拿大)
    • 概要
    • 市場規模分析·預測,年度成長率 (以金額為準,總計12年份)
    • 各國分析
  • 歐洲市場 (法國,德國等)
  • 亞太地區市場 (中國,印度等)
  • 其他的國家的市場 (RoW:南美,中東·非洲)

第9章 主要供應商分析

  • Novartis AG
    • 企業概要
    • SWOT分析
    • 近幾年的主要趨勢
  • Johnson & Johnson
  • Pfizer, Inc.
  • GlaxoSmithKline, Inc.
  • Bayer AG
  • AstraZeneca plc

第10章 分析師的全方位分析

第11章 附錄

目錄
Product Code: AV178

Report Hightlights

The antibiotics market is estimated to represent a global market of USD 43.9 billion by 2017 with growth rate of 4.9%.

Market Dynamics

Across the world, the number of individuals suffering from chronic diseases is on the rise. As per the World Health Organization (WHO), chronic disease accounts for more than 60% of all deaths, i.e. 36 million deaths out of 57 million global deaths. Antibiotics are increasingly used in the management of infectious and chronic conditions such as asthma, cystic fibrosis, COPD, and others. Thereby, the demand for antibiotics is more likely to increase for the treatment of these disease conditions, as the incidences of chronic diseases pick up. Meanwhile, numerous national and international initiatives aimed at financially incentivizing the R&D activities of antibiotics. Some of the major initiatives are New Drugs for Bad Bugs (ND4BB) program by the Innovative Medicines Initiative (IMI), Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), and Broad Spectrum Antimicrobials Program and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Such types of initiatives would, in turn, support the growth over the study period.

However, growing concern over antibiotic overuse is expected to hinder the industry growth to some extent. Overuse of these drugs may develop resistance to antimicrobial medications which is considered to be a serious public health threat to the world. According to the statement by European Centre for Disease Prevention and Control (ECDC) in November 2012, around 25,000 people die every year due to antibiotic-resistant bacterial infections in European countries.

Inhibitor Type Takeaway

By inhibitor types, the industry is divided into Protein Synthesis, Cell Wall, DNA, RNA, and other inhibitors. Cell wall synthesis inhibitors accounted for the highest share of the total market. In 2017, the segment captured around 42% share of the overall market and is projected to dominate the industry. This drug class includes antibiotics such as penicillin, cephalosporin, and Carbapenems. These are one of the most important groups of antibiotics and offers the greatest activity against gram-positive and negative bacteria. Cell wall synthesis inhibitors act by prohibiting the synthesis of the peptidoglycan layer, which is a crucial element for the structural activity of the cell wall. However, RNA segment is projected to grow with the highest growth rate and is pegged to register a 6.2% CAGR in terms of value.

Drug Class Takeaway

Drug class is categorized into Fluoroquinolones, Cephalosporin, Penicillin, Macrolides, Carbapenems, Aminoglycosides, and other. Growing by approximately 3% to 4% every year, cephalosporin drug class is the highest revenue generating segment throughout the study period. The growth of this bactericidal agent is majorly attributed to the rising demand for 4th and 5th generation therapeutics such as Ceftaroline fosamil, Cefpirome, and Ceftobiprole. On another side, aminoglycosides captured less than 5% share (i.e. lowest) of the global industry in 2017. Others segment comprise of tetracyclines, sulphonamides, monoclonal antibodies, imidazole, and many more.

Regional Takeaway

Regionally, Asia Pacific region is accounted for the largest share of the worldwide market. In 2017, the region captured almost 47% share of the overall market. Increasing prevalence of infectious and chronic diseases coupled with rising interest of global players to invest in this market support the regional growth. While the industry is on a high growth trajectory in developing regions, demand and advancement in regions like North America, and Europe is constantly increasing. Growth is mainly supported by the favorable reimbursement policies, rising demand for branded therapeutics, and increasing R&D activities.

Key Vendor Takeaway

Novartis AG, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Bayer AG, and AstraZeneca are studied in detail. The industry is largely controlled by well-established companies even though the share of small-scale players is noticeable too. Companies such as Johnson & Johnson, Pfizer, and Novartis are considered to be a giant player in this market owing to their strong product pipeline and strategic expansion.

For example, Pfizer, Inc. offers a broad range of antibiotics that includes Diflucan, Zithromax/Zmax, Unasyn, Vfend, Sulperazon, Tygacil, and others. Of these, in 2015, antibiotics such as Zyvox (USD 883 million), and Vfend (USD 682 million) recorded the highest revenue. The industry exhibits a high level of competition. Since the market is in the mature phase, barriers to entry are low. Still, in such a fragmented landscape, most antibiotic companies compete only with other local or regional players.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2014 & 2016

Base Year - 2017

Estimated Year - 2018

Projected Year - 2025

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Hospitals

Government and Regional Agencies and Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY INHIBITOR TYPE

Protein Synthesis

Cell Wall

DNA

RNA

Others

MARKET, BY DRUG CLASS

Fluoroquinolones

Cephalosporin

Penicillin

Macrolides

Carbapenems

Aminoglycosides

Other

MARKET, BY REGION

North America

U.S.

Canada

Europe

Germany

France

Rest of Europe

Asia Pacific

India

China

Rest of APAC

Rest of the World

Middle East and Africa

Latin America

TABLE OF CONTENTS

1. ANTIBIOTICS MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Key Market Facts
  • 2.2. Geographical Scenario
  • 2.3. Companies in the Market

3. ANTIBIOTICS KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. ANTIBIOTICS INDUSTRY STUDY

  • 4.1. Porter's Analysis
  • 4.2. Market Attractiveness Analysis
  • 4.3. Regulatory Framework Analysis

5. ANTIBIOTICS MARKET LANDSCAPE

  • 5.1. Market Share Analysis

6. ANTIBIOTICS MARKET - BY INHIBITOR TYPES:

  • 6.1. Overview
  • 6.2. Protein Synthesis Inhibitors
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.3. Cell Wall Inhibitors
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.4. DNA Synthesis Inhibitors
    • 6.4.1. Overview
    • 6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.5. RNA Synthesis Inhibitors
    • 6.5.1. Overview
    • 6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.6. Others
    • 6.6.1. Overview
    • 6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

7. ANTIBIOTICS MARKET - BY DRUG CLASS

  • 7.1. Overview
  • 7.2. Fluoroquinolones
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.3. Cephalosporin
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.4. Penicillin
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.5. Macrolides
    • 7.5.1. Overview
    • 7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.6. Carbapenems
    • 7.6.1. Overview
    • 7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.7. Aminoglycosides
    • 7.7.1. Overview
    • 7.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.8. Other
    • 7.8.1. Overview
    • 7.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

8. ANTIBIOTICS MARKET- BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. Overview
    • 8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 8.2.3. U.S.
    • 8.2.3.1. Overview
    • 8.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 8.2.4. Canada
    • 8.2.4.1. Overview
    • 8.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 8.3. Europe
    • 8.3.1. Overview
    • 8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 8.3.3. France
    • 8.3.3.1. Overview
    • 8.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 8.3.4. Germany
    • 8.3.4.1. Overview
    • 8.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 8.3.5. Rest of Europe
    • 8.3.5.1. Overview
    • 8.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 8.4. Asia Pacific (APAC)
    • 8.4.1. Overview
    • 8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 8.4.3. China
    • 8.4.3.1. Overview
    • 8.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 8.4.4. India
    • 8.4.4.1. Overview
    • 8.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 8.4.5. Rest of APAC
    • 8.4.5.1. Overview
    • 8.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 8.5. Rest of the World
    • 8.5.1. Overview
    • 8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 8.5.3. Latin America
    • 8.5.3.1. Overview
    • 8.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 8.5.4. Middle East and Africa
    • 8.5.4.1. Overview
    • 8.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

9. KEY VENDOR ANALYSIS

  • 9.1. Novartis AG
    • 9.1.1. Company Overview
    • 9.1.2. SWOT Analysis
    • 9.1.3. Key Developments
  • 9.2. Johnson & Johnson
    • 9.2.1. Company Overview
    • 9.2.2. SWOT Analysis
    • 9.2.3. Key Developments
  • 9.3. Pfizer, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. SWOT Analysis
    • 9.3.3. Key Developments
  • 9.4. GlaxoSmithKline, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. SWOT Analysis
    • 9.4.3. Key Developments
  • 9.5. Bayer AG
    • 9.5.1. Company Overview
    • 9.5.2. SWOT Analysis
    • 9.5.3. Key Developments
  • 9.6. AstraZeneca plc
    • 9.6.1. Company Overview
    • 9.6.2. SWOT Analysis
    • 9.6.3. Key Developments

Client can request additional company profiling as per specific requirements

10. 360 DEGREE ANALYSTVIEW

11. APPENDIX

  • 11.1. Research Methodology
  • 11.2. Abbreviations
  • 11.3. Disclaimer
  • 11.4. Contact Us

List of Tables

  • Table 1 List of Acronyms
  • Table 2 Key Market Facts, 2014 - 2025
  • Table 3 Market Drivers: Impact Analysis
  • Table 4 Market Restraint: Impact Analysis
  • Table 5 Market Opportunity: Impact Analysis
  • Table 6 PEST Analysis
  • Table 7 Porter's Five Forces Analysis
  • Table 8 Company Market Share Analysis
  • Table 9 Global Antibiotics Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • Table 10 Antibiotics Market, by Inhibitor Types, 2014 - 2025 (USD Billion)
  • Table 11 Antibiotics Market, by Drug Class, 2014 - 2025 (USD Billion)
  • Table 12 Antibiotics Market, by Geography, 2014 - 2025 (USD Billion)
  • Table 13 North America Antibiotics Market, 2014 - 2025 (USD Billion)
  • Table 14 U.S. Antibiotics Market, 2014 - 2025 (USD Billion)
  • Table 15 Canada Antibiotics Market, 2014 - 2025 (USD Billion)
  • Table 16 Europe Antibiotics Market, 2014 - 2025 (USD Billion)
  • Table 17 France Antibiotics Market, 2014 - 2025 (USD Billion)
  • Table 18 Germany Antibiotics Market, 2014 - 2025 (USD Billion)
  • Table 19 Asia Pacific Antibiotics Market, 2014 - 2025 (USD Billion)
  • Table 20 China Antibiotics Market, 2014 - 2025 (USD Billion)
  • Table 21 India Antibiotics Market, 2014 - 2025 (USD Billion)
  • Table 22 Latin America Antibiotics Market, 2014 - 2025 (USD Billion)
  • Table 23 MEA Antibiotics Market, 2014 - 2025 (USD Billion)

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Research Process Flow Chart
  • Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
  • Figure 4 Regulatory Framework Analysis
  • Figure 5 Antibiotics Market, by Inhibitor Types, 2014 - 2025 (USD Billion)
  • Figure 6 Antibiotics Market, by Drug Class, 2014 - 2025 (USD Billion)
  • Figure 7 Antibiotics Market, by Geography, 2014 - 2025 (USD Billion)